Urogen Pharma $URGN Shares Sold by Trexquant Investment LP

Key Points

• Trexquant Investment LP significantly reduced its stake in Urogen Pharma by 91.0%, selling 157,097 shares and leaving it with 15,454 shares valued at $171,000.
• Institutional investors collectively own 91.29% of Urogen Pharma, with several hedge funds increasing their positions in the company during the previous quarter.
• Urogen Pharma reported negative earnings of ($1.05) per share for the last quarter, missing estimates, while analysts have expressed mixed ratings and price targets ranging from $30.00 to $40.00 on the stock.

Trexquant Investment LP lessened its position in Urogen Pharma (NASDAQ:URGN - Free Report) by 91.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,454 shares of the company's stock after selling 157,097 shares during the period. Trexquant Investment LP's holdings in Urogen Pharma were worth $171,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. CWM LLC boosted its holdings in Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after buying an additional 5,140 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Urogen Pharma during the 4th quarter worth about $67,000. GAMMA Investing LLC raised its position in shares of Urogen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares during the last quarter. ProShare Advisors LLC bought a new stake in Urogen Pharma in the 4th quarter valued at $137,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Urogen Pharma in the 4th quarter valued at $149,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Insider Buying and Selling

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 1,520 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the transaction, the general counsel directly owned 43,305 shares in the company, valued at $827,558.55. This represents a 3.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the firm's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This represents a 6.32% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,062 shares of company stock worth $465,115. 4.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on URGN shares. HC Wainwright lowered their price objective on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Wall Street Zen raised shares of Urogen Pharma from a "sell" rating to a "hold" rating in a research report on Saturday. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Urogen Pharma in a research note on Tuesday, August 5th. Finally, Oppenheimer set a $31.00 target price on Urogen Pharma and gave the stock a "buy" rating in a research note on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $32.00.

Urogen Pharma Price Performance

URGN stock traded down $0.46 during mid-day trading on Friday, hitting $18.79. 886,418 shares of the stock were exchanged, compared to its average volume of 1,075,705. The business has a fifty day moving average price of $18.19 and a 200 day moving average price of $12.88. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $21.71. The stock has a market capitalization of $869.23 million, a price-to-earnings ratio of -5.66 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. As a group, equities analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.